Leukemia | VJHemOnc

MRD as a clinical and regulatory endpoint for AML

VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…

Zanubrutinib receives FDA approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

TKI therapy in CP-CML: toxicity management & approaching a cure

VJHemOnc is pleased to bring you a feature covering the current state of the field in the treatment CP-CML with…

Highlights in myeloid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

Genomic testing and clinical decision making in CLL

Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…

CAR-T therapy updates for the treatment of B-ALL

The introduction of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) has significantly…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

MDS diagnosis and prognosis with John Bennett

A session with myelodysplastic syndromes (MDS) expert John Bennett who discusses MDS diagnosis and prognosis.

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

VJSessions: Highlights from the 3rd European EBMT-EHA CAR T-cell Meeting Nurses Programme

A session with experts Erik Aerts, John Murray, Michelle Kenyon & Rose Ellard who cover key areas discussed during the…

The Transplant Sessions: post-ASH 2020 roundtable discussion

A session with experts Bruce Levine and Christian Chabannon, who discuss the exciting updates in transplantation and cell therapy from…

features: Leukemia